(INNF)
SOFITUZUMAB VEDOTINA(INNS)
SOFITUZUMAB VEDOTIN(INND)
SOFITUZUMAB VEDOTIN(INNC)
IMMUNOGLOBULIN G1-KAPPA AURISTATIN E CONJUGATE, ANTI-[HOMO SAPIENS MUC16 (MUCIN 16, MUC-16, CANCER ANTIGEN 125, CA125)], HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E; GAMMA1 HEAVY CHAIN (1-446) [HUMANIZED VH (HOMO SAPIENS IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -HOMO SAPIENS IGHG1*03 (CH1 R120>K (213) (117-214), HINGE (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219- 214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') - HOMO SAPIENS IGKC*01 (108'-214')]; DIMER (225-225":228-228")- BISDISULFIDE; CONJUGATED, ON AN AVERAGE OF 3 TO 4 CYSTEINYL, TO MONOMETHYLAURISTATIN E (MMAE), VIA A CLEAVABLE MALEIMIDOCAPROYLVALYL- CITRULLINYL-P-AMINOBENZYLOXYCARBONYL (MC-VAL-CIT-PABC) TYPE LINKER, RECOMMENDED INN: LIST 72(WHO)
SOFITUZUMABUM VEDOTINUM(INN)